Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 39-44

  Wang, Shui Long ^a   Hauenstein, Scott ^a   Ohrmund, Linda ^a   Shringarpure, Reshma ^a   Salbato, Jared ^a   Reddy, Rukmini ^a   McCowen, Kevin ^a   Shah, Shawn ^a   Lockton, Steven ^a   Chuang, Emil ^a   Singh, Sharat ^a  

^a Prometheus Laboratories Inc   (United States)

Author keywords

Adalimumab; Anti drug antibody; Autoimmune diseases; Immunogenicity; Mobility shift assay; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG MONITORING; DRUG TOLERANCE; FEASIBILITY STUDY; HOMOGENEOUS MOBILITY SHIFT ASSAY; HUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VALIDATION STUDY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CALIBRATION; HUMANS; LIMIT OF DETECTION; REPRODUCIBILITY OF RESULTS;

EID: 84874518073     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.01.031     Document Type: Article

References (22)

1. Suryaprasad A.G., Prindiville T. The biology of TNF blockade. Autoimmun. Rev. 2003, 2:346-357.
2. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008, 117:244-279.
3. Magro F., Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010, 24(Suppl. 1):3-14.
4. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 2009, 104:760-767.
5. Miheller P., Kiss L.S., Lorinczy K., Lakatos P.L. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. Expert Opin. Biol Ther. 2012, 12:179-192.
6. Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010, 2:233-255.
7. Emi A.N., de Carvalho J.F., Artur Almeida S.C., Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 2010, 38:82-89.
8. Colombel J.F., Feagan B.G., Sandborn W.J., Van A.G., Robinson A.M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18:349-358.
9. Wang S.L., Ohrmund L., Hauenstein S., Salbato J., Reddy R., Monk P., Lockton S., Ling N., Singh S. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J. Immunol. Methods 2012, 382:177-188.
10. Baert F., Noman M., Vermeire S., Van A.G., Haens G.D'., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.
11. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008, 20:431-435.
12. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
13. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., Li J., Pollack P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
14. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., Claes K., Coopman T., Van S.N., Van A.G., Vermeire S., Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
15. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., Dijkmans B.A., Aarden L., Wolbink G.J. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
16. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
17. West R.L., Zelinkova Z., Wolbink G.J., Kuipers E.J., Stokkers P.C., van der Woude C.J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 2008, 28:1122-1126.
18. Radstake T.R., Svenson M., Eijsbouts A.M., van Den Hoogen F.H., Enevold C., van Riel P.L., Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:1739-1745.
19. Vande Casteele N., Buurman D.J., Sturkenboom M.G., Kleibeuker J.H., Vermeire S., Rispens T., van der Kleij D., Gils A., Dijkstra G.G. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment. Pharmacol Ther. 2012, 36:765-771.
20. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006, 54:3782-3789.
21. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:921-926.
22. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., Sandborn W.J. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2010, 105:1133-1139.